RecruitingPhase 2NCT05277844
Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC
A Phase II Randomized Controlled Trial of TKI Alone Versus TKI and Local Consolidative Radiation Therapy in Oncogene Driver Mutated Oligo Metastatic Non Small Cell Lung Cancer Patients
Sponsor
Tata Memorial Hospital
Enrollment
106 participants
Start Date
Nov 11, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
A Phase II randomized controlled trial of TKI Alone versus TKI and Local Consolidative Radiation Therapy in oncogene driver mutated oligo metastatic Non-small cell lung cancer patients.
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Inclusion Criteria12
- Patients with pathologically proven diagnosis of NSCLC
- Patients with positive oncogene driver mutation (EGFR or ALK/ROS)
- Patients who have received at least 2-4 months of TKI therapy without progression
- Patients with 1-5 sites of metastatic disease not including the primary tumor and regional nodes (less than 3 metastatic lesions in one organ will be eligible and 4 or more metastatic lesions in one organ will be ineligible)
- Patients suitable for local consolidative therapy
- Adequate end-organ function CBC/differential obtained within 15 days prior to registration on study, with adequate bone marrow function defined as follows:
- Absolute neutrophil count (ANC) ≥ 500 cells/mm3;
- Platelets ≥ 50,000 cells/mm3;
- Hemoglobin ≥ 8.0 g/dl (Use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable);
- Patients with ECOG performance status of 0-2
- Age \> 18 years
- For females of child-bearing potential, negative serum or urine pregnancy test within 14 days prior to study registration
Exclusion Criteria11
- Patients with progressive disease after 2-3 months of initial TKI therapy
- Patients with negative oncogene driver mutations (EGFR/ALK/ROS)
- Patients not suitable for local consolidative radiation therapy
- Patients who are not suitable for further continuation of TKI therapy due to toxicity
- Severe, active co-morbidity defined as follows:
- Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months;
- Transmural myocardial infarction within the last 6 months;
- Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration;
- Patients with prior history of radiation therapy to thorax
- Patients with second malignancy (Synchronous or Metachronous)
- Pregnancy
Interventions
RADIATIONLocal Consolidative Radiation Therapy
Local consolidative radiation therapy to loco-regional disease and all Oligometastatic sites in addition to TKI
DRUGTKI
TKI
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05277844
Related Trials
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
NCT0536331949 locations
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT07195695192 locations
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT0711504311 locations
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
NCT06712316184 locations
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT0719024896 locations